Benchmark raised the firm’s price target on Belite Bio (BLTE) to $80 from $79 and keeps a Buy rating on the shares. In February, Belite received a positive report from an interim data analysis of the Phase 3 DRAGON trial and a DSMB recommendation to seek accelerated regulatory approval, notes the analyst, who calls out completion of the DRAGON II study around mid-year and completion of the DRAGON study by year-end 2025 as the next major catalysts for the shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLTE:
- Belite Bio, Inc. ADR: Promising Clinical Progress and Strong Financial Position Drive Buy Rating
- Promising Pipeline and Strategic Advancements: Marc Goodman Recommends ‘Buy’ for Belite Bio, Inc.
- Belite Bio’s Earnings Call: Cautious Optimism Amid Progress
- Belite Bio Announces 2025 Annual Shareholder Meeting
- Positive Buy Rating for Belite Bio, Inc. Driven by Promising Phase 3 DRAGON Trial Results and Regulatory Prospects